Västra Hamnen Corporate Finance
Capital Markets Transactions and M&As
Recent research
CombiGene: Preclinical experts in gene therapy
Swedish gene therapy specialist CombiGene focuses on discovering promising projects, developing them into the clinical phase and out-licensing them after achieving preclinical proof of concept.
Xintela: Closing in on the first license agreement
In connection with the Q1 report, Xintela announced a signed term sheet with the US firm EQGen Biomedical regarding EQSTEM, Xintela’s veterinarian joint disease treatment. We expect details to be disclosed once EQGen Biomedical secures funding and the parties announce a license agreement.
aXichem: Initiating marketing efforts in Brazil
For Q1 2024, aXichem reported sales of SEK 0.8 million, which was slightly above our estimates, but still well below what is required for the company to reach its financial target. During the quarter, aXichem was able to communicate three new collaborations attributable to aXivite. Two of these, Silver Fern Brand and Triquetra Health, are for the US market, while the agreement with Silvaco is for the Scandinavian market.
Bioextrax: Going from research to development
In 2024, Bioextrax will show its ablitiy to convert promising projects into commercial deals. The company gave an update on the main projects, including the candy producer, the cosmetics company and the waste management company. The report did not prompt any major changes in our model, and we keep our fair value of SEK 7.60 per share.
Market Focus
Market focus is our service for stock analysis of small and medium-sized listed companies. The service contributes to increased turnover in the share by increasing investors' awareness of the company and attention to current events. All our analyses are listed below.
Market Focus
Register for Market Focus updates
About us
We help our customers grow
Västra Hamnen Corporate Finance is an independent securities company that provides advice in connection with corporate transactions.
"We love small companies and do our best every day to be their first choice in connection with listing processes and capitalizations."